These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 31439048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice.
    Kim SP, Srivatsan SN, Chavez M, Shirai CL, White BS, Ahmed T, Alberti MO, Shao J, Nunley R, White LS, Bednarski J, Pehrson JR, Walter MJ.
    Cell Rep; 2021 Aug 31; 36(9):109626. PubMed ID: 34469727
    [Abstract] [Full Text] [Related]

  • 3. Molecular dissection of the 5q deletion in myelodysplastic syndrome.
    Ebert BL.
    Semin Oncol; 2011 Oct 31; 38(5):621-6. PubMed ID: 21943668
    [Abstract] [Full Text] [Related]

  • 4. The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS.
    Lane SW, Sykes SM, Al-Shahrour F, Shterental S, Paktinat M, Lo Celso C, Jesneck JL, Ebert BL, Williams DA, Gilliland DG.
    Blood; 2010 Apr 29; 115(17):3489-97. PubMed ID: 20197553
    [Abstract] [Full Text] [Related]

  • 5. Recurrent genetic defects on chromosome 5q in myeloid neoplasms.
    Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP.
    Oncotarget; 2017 Jan 24; 8(4):6483-6495. PubMed ID: 28031539
    [Abstract] [Full Text] [Related]

  • 6. The molecular pathogenesis of the myelodysplastic syndromes.
    Pellagatti A, Boultwood J.
    Eur J Haematol; 2015 Jul 24; 95(1):3-15. PubMed ID: 25645650
    [Abstract] [Full Text] [Related]

  • 7. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.
    Nilsson L, Astrand-Grundström I, Arvidsson I, Jacobsson B, Hellström-Lindberg E, Hast R, Jacobsen SE.
    Blood; 2000 Sep 15; 96(6):2012-21. PubMed ID: 10979941
    [Abstract] [Full Text] [Related]

  • 8. 5q- syndrome.
    Boultwood J, Pellagatti A, Wainscoat JS.
    Curr Pharm Des; 2012 Sep 15; 18(22):3180-3. PubMed ID: 22571696
    [Abstract] [Full Text] [Related]

  • 9. Haploinsufficiency of Apc leads to ineffective hematopoiesis.
    Wang J, Fernald AA, Anastasi J, Le Beau MM, Qian Z.
    Blood; 2010 Apr 29; 115(17):3481-8. PubMed ID: 20065296
    [Abstract] [Full Text] [Related]

  • 10. Deletion 5q MDS: molecular and therapeutic implications.
    Komrokji RS, Padron E, Ebert BL, List AF.
    Best Pract Res Clin Haematol; 2013 Dec 29; 26(4):365-75. PubMed ID: 24507813
    [Abstract] [Full Text] [Related]

  • 11. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells.
    Dutt S, Narla A, Lin K, Mullally A, Abayasekara N, Megerdichian C, Wilson FH, Currie T, Khanna-Gupta A, Berliner N, Kutok JL, Ebert BL.
    Blood; 2011 Mar 03; 117(9):2567-76. PubMed ID: 21068437
    [Abstract] [Full Text] [Related]

  • 12. Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
    Fernandez-Mercado M, Burns A, Pellagatti A, Giagounidis A, Germing U, Agirre X, Prosper F, Aul C, Killick S, Wainscoat JS, Schuh A, Boultwood J.
    Haematologica; 2013 Dec 03; 98(12):1856-64. PubMed ID: 23831921
    [Abstract] [Full Text] [Related]

  • 13. Dyserythropoiesis of myelodysplastic syndromes.
    Lefèvre C, Bondu S, Le Goff S, Kosmider O, Fontenay M.
    Curr Opin Hematol; 2017 May 03; 24(3):191-197. PubMed ID: 28072603
    [Abstract] [Full Text] [Related]

  • 14. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
    Harada H.
    Rinsho Ketsueki; 2017 May 03; 58(10):1941-1950. PubMed ID: 28978836
    [Abstract] [Full Text] [Related]

  • 15. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.
    An N, Khan S, Imgruet MK, Gurbuxani SK, Konecki SN, Burgess MR, McNerney ME.
    Blood; 2018 Jun 14; 131(24):2682-2697. PubMed ID: 29592892
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1.
    Fei DL, Zhen T, Durham B, Ferrarone J, Zhang T, Garrett L, Yoshimi A, Abdel-Wahab O, Bradley RK, Liu P, Varmus H.
    Proc Natl Acad Sci U S A; 2018 Oct 30; 115(44):E10437-E10446. PubMed ID: 30322915
    [Abstract] [Full Text] [Related]

  • 18. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway.
    Payne EM, Virgilio M, Narla A, Sun H, Levine M, Paw BH, Berliner N, Look AT, Ebert BL, Khanna-Gupta A.
    Blood; 2012 Sep 13; 120(11):2214-24. PubMed ID: 22734070
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.